Market Overview

Morgan Stanley Reiterates Overweight Rating on Gilead Sciences on Phase III Data

Share:
Related GILD
ImmunoVaccine Up 24% On Deal With Gilead Sciences
Gilead Booking Profits Overseas On A $1,000 Pill: Hard To Swallow
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog (Zacks)

In a report published Monday, Morgan Stanley reiterated its Overweight rating on Gilead Sciences (NASDAQ: GILD).

Morgan Stanley noted, “Additional Phase III data for 7977/sofosbuvir are as expected and continue to support a best in class profile and a multi-billion dollar opportunity for Gilead with a likely launch in 1H14. Despite investor concern around FISSION, a similar 67% SVR rate to PEG-riba for an all-oral 12-week regimen looks solid, but GT2/3 remains a more minor part of the long term opportunity (~30% of US patients). For NEUTRINO in GT1 with PEG-riba, an 89% SVR rate in GT1 looks good and use in this setting could be an early source of launch upside ahead of the all-oral GT1 approval in 2015. Discontinuation rates of 1% in FISSION and 2% in NEUTRINO continue to support 7977's strong safety profile. The program is on track for a mid-2013 filing with full Phase III data for both likely at EASL in April.”

Gilead Sciences closed on Friday at $40.56.

Latest Ratings for GILD

DateFirmActionFromTo
Feb 2015Credit SuisseDowngradesOutperformNeutral
Feb 2015CitigroupMaintainsBuy
Feb 2015UBSMaintainsBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GILD)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→